Studies at the American Heart Association show very different approaches to exercise for type 2 diabetes patients.
This year’s theme of promoting healthier lifestyles continued at Tuesday’s poster session at the American Heart Association Scientific Sessions, with researchers presenting different approaches to exercise for patients with type 2 diabetes (T2D).
Bursts of exercise. Short periods of intense exercise may be best for those with newly diagnosed T2D, according to a study whose lead author is an undergraduate student at the University of Western Ontario in London, Ontario.
Cholesterol levels, blood sugar, and weight improved greatly among T2D patients who had 10 minutes of high-intensity exercise 3 times a day, 5 days a week, compared with a group who exercised on a more traditional schedule of 30 minutes at a lower intensity, also for 5 days a week. The study involved 76 patients, 70% male, who were recruited shortly after being diagnosed with T2D.
Burst exercise patients actually ended up getting more activity overall, and had 2.3 times greater improvement in glycated hemoglobin levels and 3 times the reduction in their body mass index (BMI) than their counterparts in the traditional exercise program. The burst patients outperformed the traditional patients on stressed tests and did better on cholesterol screenings.
The study’s lead author, Avinash Pandey, speculated that it may be easier to fit the short periods of exercise into busy schedules. “People randomized to that regimen were more consistent with exercise and ended up doing more exercise per week,” he said in a statement. In his abstract, Pandey said the level was actually 27% more.1
Yale study. The National Institutes of Health (NIH) paid for a study that looked for ways to get rid of the high amounts of visceral fat that come with insulin resistance, which can lead to T2D as well as cardiovascular disease. A team from Yale University led by Soohyn Nam randomized 77 participants ages 35 to 65 years of age who had T2D or prediabetes, to either a diet for 6 months or a diet combined with supervised moderate intensity exercise training. In the group, 37 already had T2D and 40 had prediabetes.
Outcomes in the study were visceral and subcutaneous fat volumes, which were measured through magnetic resonance imaging (MRI); aerobic fitness, as measured by VO2 peak during a treadmill test, body mass index (BMI), and glycated hemoglobin levels (A1C).
Of the 77 subjects (mean age 54.8 years, mean BMI 34.5), there was substantial average weight loss in both groups, but wide variation within each group, and this showed up in the similarity in all the measures between the diet only and diet exercise groups. The 2 groups did not differ substantially in their changes for body weight: the diet group had lost 6.04 kg while the diet and exercise group had lost an average of 6.68 kg. For abdominal fat, results were also about the same: the diet only group lost 101.93 cm2 and the diet and exercise group was a fraction lower at 104.15 cm2. In visceral fat reductions, the diet only group did slightly better but not much, -25.53 cm2 vs -23.24 cm2. Measures of A1C were also nearly identical.2
What the study showed, the researchers said, was that when patients with T2D or prediabetes can manage to lose belly fat, they will see improved A1C. The trouble is, not all do.
References
1. Pandey A. Poirer P. The impacts of burst exercise compared to sustained exercise on the cardiometabolic status and exercise behavior of newly diagnosed type 2 diabetic patients. Presented at the American Heart Association Scientific Sessions; Orlando, Florida, November 10, 2015; poster T-2088.
2. Nam S, Dobrosielski DA, Stewart KJ et al. Effect of a lifestyle weight loss intervention on visceral fat and glycemic control among individuals with and without type 2 diabetes. Presented at the American Heart Association Scientific Sessions; Orlando, Florida; November 10, 2015; poster T-2091.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More